Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Prostate cancer screening

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    266 result(s) found for: Prostate cancer screening. Displaying page 1 of 14.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2013-004405-30 Sponsor Protocol Number: ARN-AR18-CT-102 Start Date*: 2014-02-12
    Sponsor Name:Arno Therapeutics Inc
    Full Title: A Phase 1 Study of Onapristone in Patients with Advanced Castration-resistant Prostate Cancer
    Medical condition: Advanced Castration-resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036920 Prostate cancer stage IV PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036911 Prostate cancer recurrent PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036910 Prostate cancer NOS LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066489 Progression of prostate cancer LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-001192-39 Sponsor Protocol Number: P11-1 Start Date*: 2012-01-26
    Sponsor Name:Dendreon Corporation
    Full Title: AN OPEN-LABEL STUDY OF SIPULEUCEL-T IN EUROPEAN MEN WITH METASTATIC, CASTRATE RESISTANT PROSTATE CANCER
    Medical condition: metastatic castrate resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036910 Prostate cancer NOS LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066489 Progression of prostate cancer LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036916 Prostate cancer stage D LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Completed) GB (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-012405-18 Sponsor Protocol Number: 09/0221 Start Date*: 2010-02-15
    Sponsor Name:University College London
    Full Title: Single site, phase II, double blind, randomised, placebo controlled study of the effect of dutasteride (Avodart)0.5 mg on the volume and characteristics of prostate cancer, as assessed by multifunc...
    Medical condition: Low risk prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2007-006055-39 Sponsor Protocol Number: FE200486 CS26 Start Date*: 2008-01-30
    Sponsor Name:Ferring Pharmaceuticals A/S
    Full Title: An Open-Label, Multi-Centre, Randomised Parallel-Group Study, Investigating Efficacy and Safety of Different Degarelix Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring Androge...
    Medical condition: Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007113 Cancer of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: HU (Completed) FI (Prematurely Ended) CZ (Prematurely Ended) BE (Completed) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-021900-93 Sponsor Protocol Number: CLIN1001 PCM301 Start Date*: 2010-12-14
    Sponsor Name:STEBA BIOTECH SA
    Full Title: A European randomised Phase 3 study to assess the efficacy and safety of TOOKAD® Soluble for low risk localised prostate cancer compared to Active Surveillance
    Medical condition: Low-risk prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10060862 Prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed) GB (Completed) DE (Completed) NL (Completed) BE (Completed) SE (Completed) FI (Completed) DK (Completed) ES (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000101-69 Sponsor Protocol Number: EGD-EC-005 Start Date*: 2013-07-04
    Sponsor Name:Astellas Pharma Europe Ltd. (APEL)
    Full Title: An exploratory, open label, single-arm study to evaluate the effect of Eligard® 6-month on biomarkers of disease in patients with metastatic prostate cancer.
    Medical condition: Patients with metastatic prostate cancer whom androgen deprivation therapy (ADT) is indicated
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10007113 Cancer of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-005665-12 Sponsor Protocol Number: MDV3100-14(C3431005) Start Date*: 2013-09-06
    Sponsor Name:Medivation, Inc., a wholly owned subsidiary of Pfizer Inc.
    Full Title: A Multinational, Phase 3, Randomized, Double Blind, Placebo Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration Resistant Prostate Cancer
    Medical condition: Patients With Nonmetastatic Castration Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) IT (Completed) AT (Completed) BE (Completed) GB (GB - no longer in EU/EEA) SK (Completed) FI (Completed) NL (Completed) ES (Completed) GR (Completed) FR (Completed) DK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-001650-77 Sponsor Protocol Number: FE200486 CS18 Start Date*: 2007-05-14
    Sponsor Name:Ferring Pharmaceuticals A/S
    Full Title: An Open-Label, Multi-Centre, Randomised Parallel-Group Dose-Finding Study, Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring ...
    Medical condition: Patients with prostate cancer requiring androgen ablation therapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060862 Prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: HU (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2010-021287-16 Sponsor Protocol Number: 9785-CL-0321 Start Date*: 2010-11-29
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A phase 2, open-label, single-arm, efficacy and safety study of MDV3100 in patients with hormone-naïve prostate cancer
    Medical condition: Hormone-naïve prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10007113 Cancer of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Completed) CZ (Completed) DE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-002880-98 Sponsor Protocol Number: CRO-04-62 / GP/C/03/PRO Start Date*: 2005-11-25
    Sponsor Name:GP-Pharm s.a.
    Full Title: Efficacy and safety of a new Leuprolide acetate 3.75 mg depot formulation, GP-Pharm s.a., when given as palliative treatment to prostate cancer patients
    Medical condition: prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    6.0 10007113 LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Completed) GB (Completed) CZ (Completed) HU (Completed) IT (Completed) DE (Completed) SK (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-005964-24 Sponsor Protocol Number: CRO-06-78 / DSC/06/LEU15/01 Start Date*: 2007-04-03
    Sponsor Name:Italfarmaco S.p.A.
    Full Title: Pharmacokinetics, pharmacodynamics and safety of a new Leuprolide acetate 22.5 mg depot formulation, when given as palliative treatment to prostate cancer patients
    Medical condition: Prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10007113 Cancer of prostate LLT
    Population Age: Adults Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-004351-29 Sponsor Protocol Number: 2008-02-IMP-5 Start Date*: 2008-12-18
    Sponsor Name:HEXAL AG
    Full Title: OPEN LABEL, MULTICENTER STUDY ON PHARMACOKINETICS, PHARMACODYNAMICS, EFFICACY AND SAFETY OF GOSERELIN 10.8 mg IMPLANT HEXAL IN PATIENTS WITH ADVANCED HORMONE DEPENDENT PROSTATE CANCER
    Medical condition: Palliative treatment of advanced hormone dependent prostate cancer.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060862 Prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2015-000860-32 Sponsor Protocol Number: UMCN-AKF-14.17 Start Date*: 2015-04-28
    Sponsor Name:Radboud University Medical Center
    Full Title: Personalizing enzalutamide (Xtandi®) therapy by understanding the relation between the decrease in the expression profile of a panel of preselected microRNAs, tumor related mRNAs and treatment resp...
    Medical condition: Metastatic Castration Resistant Prostate Cancer (mCRPC)
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-001703-38 Sponsor Protocol Number: ARI109924 Start Date*: 2007-09-25
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A Randomised, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Dutasteride (AVODART™) 0.5 mg in Extending the Time to PSA Doubling in Men with Prostate Cancer and Biochem...
    Medical condition: Clinically localised prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060862 Prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FI (Completed) SE (Completed) FR (Completed) ES (Completed) LT (Prematurely Ended) LV (Prematurely Ended) NL (Completed) GB (Completed) EE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-002132-94 Sponsor Protocol Number: CZOL446EDE28 Start Date*: 2008-08-18
    Sponsor Name:Novartis Pharma GmbH
    Full Title: „Effect of intravenous Zoledronic Acid on Bone Metabolism given over 4 month in patients with prostate cancer or breast cancer and bone metastasis. A prospective, single-arm multicenter study” (Z...
    Medical condition: Patients with prostate or breast cancer with bone metastasis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036910 Prostate cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004513-90 Sponsor Protocol Number: UMCN-AKF-14.07 Start Date*: 2015-03-17
    Sponsor Name:Radboud UMC
    Full Title: Optimizing abiraterone (Zytiga®) therapy by exploring the relation between an early biomarker - drug exposure - as a predictor for drug response in patients with mCRPC (OPTIMUM - STUDY)
    Medical condition: Metastatic Castration Resistant Prostate Cancer (mCRPC)
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000075-16 Sponsor Protocol Number: BAY88-8223/16216 Start Date*: 2012-06-20
    Sponsor Name:Bayer HealthCare AG
    Full Title: Radium-223 Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients with Bone Metastasis
    Medical condition: Castrate Resistant Prostate Cancer/Hormone-Refractory Prostate Cancer patients with bone metastasis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10036916 Prostate cancer stage D LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) DE (Completed) NO (Completed) FI (Completed) BE (Completed) ES (Completed) CZ (Completed) IE (Completed) GB (Completed) IT (Completed) DK (Prematurely Ended) NL (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-005465-36 Sponsor Protocol Number: 62202-761 Start Date*: 2009-04-29
    Sponsor Name:Meletios Athanasios Dimopoulos
    Full Title: Pilot study of the significance of PTEN expression in patients with hormone refractory prostate cancer (HRPC) treated with Cetuximab as monotherapy for 8 weeks, followed by Docetaxel plus Cetuximab
    Medical condition: Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060862 Prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2009-016200-23 Sponsor Protocol Number: C_30060_P3_03 Start Date*: 2009-12-15
    Sponsor Name:Acino Supply AG
    Full Title: An open label, multiple dose Phase III clinical study in patients with prostate cancer to investigate the clinical efficacy and safety of a new GnRH implant (ACINO Goserelin 10.8 mg Implant) applie...
    Medical condition: prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    12.0 10060862 Prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-005276-27 Sponsor Protocol Number: FE 200486 CS35 Start Date*: 2009-07-17
    Sponsor Name:Ferring Pharmaceuticals A/S
    Full Title: An Open-Label, Multi-Centre, Randomised, Parallel-Arm One-Year Trial, Comparing the Efficacy and Safety of Degarelix Three-Month Dosing Regimen with Goserelin Acetate in Patients with Prostate Canc...
    Medical condition: prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: HU (Completed) NL (Completed) DE (Completed) FI (Completed) CZ (Completed) GB (Completed) BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 06:04:03 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA